Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30761909 | 0.90 | CASP3 (0.66) | CASP3KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL27377656 | 0.90 | CASP3 (0.66) | CASP3KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL30761908 | 0.90 | CASP3 (0.66) | CASP3KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL29401676 | 0.85 | CASP3 (0.56) | CASP3MEN1KMT2AALDH1A1POLB | |
| SCHEMBL4338734 | 0.85 | CASP3 (0.56) | CASP3MEN1KMT2AALDH1A1POLB | |
| SCHEMBL18669155 | 0.81 | KMT2A (0.75) | CASP3KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL1362352 | 0.81 | HPGD (0.49) | CASP3MEN1KMT2AALDH1A1POLB | |
| SCHEMBL31752966 | 0.80 | KMT2A (0.63) | CASP3KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL45154 | 0.79 | CASP3 (0.88) | CASP3KDM4EMEN1KMT2AAPAF1 | |
| SCHEMBL30296449 | 0.79 | CASP3 (0.88) | CASP3KDM4EMEN1KMT2AAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| EP-3055302-B1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3055302-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160221945-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CASP3 2425/4885KDM4E 4125/4885MEN1 4474/4885 |
| US-20180282272-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CASP3 2425/4885KDM4E 4125/4885MEN1 4474/4885 |
| US-20180118680-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CASP3 2425/4885KDM4E 4125/4885MEN1 4474/4885 |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | CASP3 2425/4885KDM4E 4125/4885MEN1 4474/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | CASP3 2425/4885KDM4E 4125/4885MEN1 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.